Detalles de la búsqueda
1.
Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer.
EMBO J
; 33(12): 1365-82, 2014 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24837709
2.
A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.
J Pathol
; 236(4): 517-30, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25875424
3.
Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer.
J Cell Mol Med
; 19(4): 723-33, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25639644
4.
A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer.
BMC Cancer
; 14: 352, 2014 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-24886074
5.
Lactate transporters in the context of prostate cancer metabolism: what do we know?
Int J Mol Sci
; 15(10): 18333-48, 2014 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-25314297
6.
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer.
Prostate
; 73(7): 763-9, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23192371
7.
Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer.
BMC Cancer
; 11: 312, 2011 Jul 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-21787388
8.
Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Oxid Med Cell Longev
; 2020: 2148562, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32411320
9.
Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.
Mol Cancer Res
; 17(2): 446-456, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30333152
10.
MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.
Cancer Epidemiol Biomarkers Prev
; 27(2): 201-207, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29141848
11.
Identification of potential therapeutic targets in prostate cancer through a cross-species approach.
EMBO Mol Med
; 10(3)2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29437778
12.
Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.
Oncotarget
; 7(20): 28891-902, 2016 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27049720
13.
Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
J Natl Cancer Inst
; 108(5)2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26657335
14.
Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer.
Oncotarget
; 6(25): 21675-84, 2015 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-26035357
15.
T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness.
Clin Cancer Res
; 20(18): 4949-61, 2014 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25009296
Resultados
1 -
15
de 15
1
Próxima >
>>